| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:1056-1062.)
© 2006 American Heart Association, Inc.
Pediatric Cardiology |
From the School of Kinesiology and Health Studies (C.J.J., I.J.) and Department of Community Health and Epidemiology (I.J.), Queens University, Kingston, Ontario, Canada.
Reprint requests to Ian Janssen, PhD, School of Kinesiology and Health Studies, Queens University, 69 Union St, Kingston, Ontario, Canada, K7L 3N6. E-mail janssen{at}post.queensu.ca
Received February 13, 2006; revision received June 13, 2006; accepted June 23, 2006.
| Abstract |
|---|
|
|
|---|
Methods and Results Data from the National Health and Nutrition Examination Surveys were used to develop age- and gender-specific thresholds that can be used to denote abnormal levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Each curve was linked to the adult National Cholesterol Education Program Adult Treatment Panel III lipoprotein thresholds using LMS (Lambda-Mu-Sigma) growth curve regression methods. A series of growth curves and tables are presented that can be used to diagnose high-risk lipoprotein levels in the clinical and research settings. For example, in 1-year increments for males starting at age 12 and extending to age 19 years, the high-risk thresholds for total cholesterol were 6.03, 5.83, 5.70, 5.70, 5.77, 5.88, 6.02, and 6.16 mmol/L. The corresponding high-risk threshold for adults (
20 years) is 6.22 mmol/L.
Conclusions The present study is the first attempt at developing age- and gender-specific lipoprotein threshold concentrations for adolescents. This new classification system should provide a more accurate diagnosis of high-risk lipoprotein levels and associated cardiovascular risks in adolescents.
Key Words: cholesterol hypercholesterolemia lipoproteins adolescent
| Introduction |
|---|
|
|
|---|
Editorial p 989
Clinical Perspective p 1062
The National Cholesterol Education Program (NCEP) has published cutpoints that can be used to identify youth with abnormal total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels, as shown in Table 1.8 The cutpoints for borderline-abnormal and abnormal lipoprotein concentrations are represented by the 75th and 95th percentiles (25th and 5th for HDL-C) of the population distribution and apply to all youth 2 to 19 years of age. Research indicates that these percentiles have a limited ability to predict the youth who, when adults, will have high-risk lipoprotein levels, as defined by the NCEP.9 Several other concerns underlie the pediatric NCEP classification system. First, lipoprotein concentrations change considerably with normal growth and maturation and vary by gender,1012 which is not reflected by these cutpoints. Second, the 75th and 95th percentiles (25th and 5th for HDL-C) were chosen arbitrarily and have no clinical or health meaning (ie, why not use the 90th percentile instead of the 95th?). Third, the NCEP cutpoints are based on the population distribution of the late 1980s, and the distribution of these lipoproteins, particularly TGs, has changed over time.13,14
|
Given the concerns with the current pediatric NCEP classification system, the present study developed new age- and gender-specific lipoprotein cutpoints for adolescents 12 to 20 years of age. These cutpoints are linked to the adult health-based thresholds for abnormal lipoproteins (Table 2) and thus are indirectly linked to health risk.
|
| Methods |
|---|
|
|
|---|
Study Population
The NHANES surveys included a home interview and a standardized clinical examination performed in a mobile examination center. The analysis of the combined datasets was limited to adolescents aged 12 to 20 years who completed both the home interview and the mobile examination center examination and who had measurements of fasting (
6 hours as per NHANES protocol) blood lipoproteins. Participants younger than 12 years of age were not requested to fast before blood sampling and therefore were not included in the analysis. This resulted in 6067 participants from all 3 surveys (2921 males and 3146 females).
Lipoprotein Measurements
Blood samples were collected during the mobile examination center examination according to standardized procedures. In each survey, lipoproteins were analyzed at the Johns Hopkins University Lipoprotein Analytical Laboratory. Details of the protocol are found in the NHANES laboratory procedures manuals.1618 Briefly, lipoproteins were measured enzymatically in a series of coupled reactions in which cholesterol ester and triglyceride were hydrolyzed to cholesterol and glycerol, respectively. LDL-C was estimated from TC, HDL-C, and TG with the Friedewald formula.19 TC and HDL-C were measured in every subject who participated in a mobile examination center examination; however, TG was only measured in a morning subsample of the study population, ie, those who were examined before noon. Therefore, LDL-C was estimated only for those in the morning subsample.
Development of the Adolescent Lipoprotein Classification System
Age- and gender-specific growth curves were developed for TC, LDL-C, HDL-C, and TG, the 4 lipoproteins used in clinical practice, by the LMS method.20 The distribution of each lipoprotein is summarized by 3 age-specific curves known as Lambda (L), Mu (M), and Sigma (S). The L curve accounts for the skewness in the distribution of the data, whereas the M and S curves represent the median and coefficient of variance, respectively, at each age. The values of L, M, and S can be computed for a series of ages and are used to plot the growth curves. The points on each growth curve are defined by the following formula:
|
|
where L, M, and S are the values of the respective curves at each age, and z is the z score that corresponds to the percentile of the curve. The underlying assumption of the LMS method is that after a suitable power transformation, the distribution of the data at each age is normal.
The first step in creating the lipoprotein growth curves was to define the z score at age 20.0 years for each of the NCEP (Adult Treatment Panel III [ATP III]) adult lipoprotein cutpoints, as shown in Table 2.21 The evidence- and health-based adult cutpoints reflect the findings of prospective cohort studies and clinical trials.21 The cutpoints represent the point at which CVD risk increases (ie, risk is moderately increased within the borderline-high range and substantially increased within the high range). The z scores at age 20 were calculated with the following formula22: equation
|
|
where Y is the adult lipoprotein cutpoint and L, M, and S are the values at age 20.0 years. For example, the adult cutpoint for borderline-high TG is 1.695 mmol/L, which corresponds to a z score of 1.23 and is equivalent to the 89th percentile for males at exactly 20.0 years of age. This age was used to create the percentile for each growth curve because it is the age at which the adult lipoprotein cutpoints are initiated. By defining the percentile at age 20.0 years, the adolescent cutpoints are directly linked to the adult cutpoints, which in turn are linked to CVD risk.
In the second step, the age-specific curves were created by regressing the percentiles at age 20.0 years backward through the distributional growth curve of the respective lipoproteins. Each point on the curve was calculated using the predefined z score and the age-specific values of L, M, and S as defined in the first equation. Therefore, each percentile curve defines a series of age-specific cutpoints throughout adolescence that correspond to the adult cutpoint. For example, the percentile curve for borderline-high TG passes exactly though the adult cutpoint of 150 mg/dL at 20.0 years of age.
Although these percentile curves were derived from cross-sectional data, we propose that they will be useful for tracking changes in an adolescents risk over time and not just for assessing risk at a given time point. This approach assumes that an adolescents lipoprotein percentile will remain relatively constant as he or she ages (unless a lifestyle change occurs or other treatment is given), a position that is supported by many47 but not all23 longitudinal studies that have tracked lipoproteins.
The NHANES surveys used a weighted sampling design, and the data were analyzed accordingly. Participants examined in the morning subsample were assigned a different weighting; thus, LDL-C and TG had different weightings than did TC and HDL-C. The NHANES datasets were managed in SAS version 8.02 (SAS Institute, Cary, NC), and the percentile curves were developed with LMS Pro software, version 1.16 (Institute of Child Health, London, United Kingdom).
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
|
|
|
|
|
The male (Figure 1A) and female (Figure 2A) growth curves for borderline-high and high TC concentrations followed a similar trajectory: TC concentrations declined during early adolescence and rose thereafter, approaching adult concentrations. Each curve was linked to the corresponding adult cutpoint such that the borderline-high-risk curve passes through 5.18 mmol/L and the high-risk curve passes through 6.22 mmol/L at 20.0 years of age. The borderline-high and high TC curves represent the 86th and 97th percentiles for males and the 78th and 94th percentiles for females, respectively.
Figures 1B and 2
B represent the growth curves for near-borderline-high, borderline-high, and high LDL-C concentrations. Although the male and female LDL-C curves passed through the same adult cutpoints at 20.0 years of age, they did not follow similar trajectories. The male LDL-C risk curves decreased during early adolescence before increasing at &15.5 years of age, whereas those for females steadily increased from 12.0 to 20.0 years of age. The near-borderline-high, borderline-high, and high LDL-C growth curves represent the 54th, 86th, and 98th percentiles for males and the 53rd, 83rd, and 98th percentiles for females, respectively.
The growth curves for low and protective HDL-C concentrations are shown in Figures 1C and 2
C for males and females, respectively. The low HDL-C curve for males declined slightly until 16 years of age, after which it did not change through young adulthood. On the other hand, the female curve for low HDL-C did not change with age during adolescence. The low and protective HDL-C growth curves were represented by the 26th and 87th percentiles in males and the 27th and 73rd percentiles in females, respectively.
The male (Figure 1D) and female (Figure 2D) growth curves for borderline-high and high TG did not follow similar trajectories: Whereas the male curves increased with age in a linear manner, the female curves declined during early adolescence before increasing to approach adult concentrations. The borderline-high and high TG curves represent the 88th and 95th percentiles for males and the 89th and 95th percentiles for females, respectively.
| Discussion |
|---|
|
|
|---|
In most clinical settings, not every adolescent is screened for high-risk lipoprotein values. The NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents recommends that selective screening take place among youth at high risk of dyslipidemia and CVD in adulthood8; that is, adolescents are screened on the basis of the presence of parental dyslipidemia or family history of premature CVD (any parent or grandparent diagnosed with CVD before the age of 55 years).8 Initially, nonfasting TC should be measured. If nonfasting TC is within the borderline-high or high range, then a fasting lipoprotein analysis should be obtained.8 We recommend maintaining the current NCEP screening guidelines; however, we believe that the cutpoints developed in the present study will improve the identification of youth with high-risk values. Also, given the intrinsic variability of lipoprotein values, it is ideal to have multiple lipoprotein measurements over time to classify a patient into a risk category.8,21,23
There are several benefits to the lipoprotein classification system developed in the present study compared with the NCEP system that is currently used for the pediatric population. First, the age- and gender-specific threshold values reflect the natural fluctuation in lipoprotein concentrations that occur with growth and maturation. Thus, adolescents should not be misdiagnosed simply because they are on a different part of the growth curve. Several hypotheses have been proposed to explain the changes in lipoprotein concentrations that occur during adolescence2527; more research, however, is warranted in this field.
A second advantage of the classification system developed in the present study is that the same proportion of at-risk adolescents will be identified at each age. For example, the borderline-high TC thresholds identify 14% of the male adolescent population irrespective of age. Conversely, using the existing NCEP classification system 50% of 10-year-olds compared with 25% of 13-year-olds would be diagnosed with borderline-high TC.10 Third, the new adolescent lipoprotein thresholds are linked to the adult NCEP ATP III values, which themselves are based on increased risk of CVD, as previously discussed in the Methods. This eliminates some of the arbitrariness inherent to the percentile approach used in the current NCEP guidelines for youth and should provide a more accurate assessment of CVD risk status among adolescents.
Several limitations of this study should be recognized. First, the development of the classification systems was limited to adolescents 12 to 20 years of age. Because lipoprotein concentrations vary with age from birth through adulthood, lipoprotein cutpoints ideally would have been developed for all ages (2 to 20 years). However, to obtain accurate lipoprotein measurements, fasting blood samples must be collected. Requesting fasting blood samples from young children is rarely done in experimental settings and was not done in children under 12 years of age in the NHANES surveys.
Second, it is possible that race-specific lipoprotein thresholds would provide a more accurate assessment of risk status. Because the adult NCEP ATP III lipoprotein thresholds are not race specific, and because we wanted to link the adolescent cutpoints to those of the ATP III, we did not develop race-specific growth curves and thresholds. Another limitation to consider in the present study is that it would have been ideal to directly link the new adolescent lipoprotein thresholds to CVD risk. However, because CVD is a chronic disease of late onset, it is very difficult to establish a direct link between adolescent lipoprotein concentrations and CVD outcomes without having an exceptionally long follow-up period.
Lastly, the NHANES surveys are cross-sectional in design. A key assumption, therefore, is that the lipoprotein percentiles for an individual are maintained as he/she ages. Although it is well known that lipoprotein concentrations track well from adolescence into adulthood,57 the new lipoprotein classification systems need to be validated with longitudinal studies to establish whether they provide a more sensitive and specific assessment of CVD risk than the current NCEP adolescent guidelines.
The present study presents the first attempt to create age- and gender-specific lipoprotein thresholds for adolescents. It is only intuitive that lipoprotein risk curves be developed, given that pediatricians have used height, weight, body mass index, and blood pressure growth curves for years.24,28,29 We have developed 2 alternatives for clinical use, growth curves and tables, both of which are convenient and user friendly. We encourage clinicians and researchers to adopt this new classification system because it should provide a more accurate diagnosis of adolescents with high-risk lipoprotein values and associated cardiovascular health risks.
| Acknowledgments |
|---|
Sources of Funding
This study was supported by the Canadian Institutes of Health Research (MOP 74632; Dr Janssen). C. Jolliffe was supported by an Ontario Graduate Scholarship.
Disclosures
None.
| References |
|---|
|
|
|---|
| Footnotes |
|---|
Related Article:
Circulation 2006 114: 985.
This article has been cited by other articles:
![]() |
P. O. Kwiterovich Cut Points for Lipids and Lipoproteins in Children and Adolescents: Should They Be Reassessed? Clin. Chem., July 1, 2008; 54(7): 1113 - 1115. [Full Text] [PDF] |
||||
![]() |
C. G. Magnussen, O. T. Raitakari, R. Thomson, M. Juonala, D. A. Patel, J. S.A. Viikari, J. Marniemi, S. R. Srinivasan, G. S. Berenson, T. Dwyer, et al. Utility of Currently Recommended Pediatric Dyslipidemia Classifications in Predicting Dyslipidemia in Adulthood: Evidence From the Childhood Determinants of Adult Health (CDAH) Study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study Circulation, January 1, 2008; 117(1): 32 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Velasquez-Mieyer, C. P. Neira, R. Nieto, and P. A. Cowan Review: Obesity and cardiometabolic syndrome in children Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 61 - 81. [Abstract] [PDF] |
||||
![]() |
S. Ardoin, C. Sandborg, and L. Schanberg Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 618 - 626. [Abstract] [PDF] |
||||
![]() |
B. W. McCrindle, E. M. Urbina, B. A. Dennison, M. S. Jacobson, J. Steinberger, A. P. Rocchini, L. L. Hayman, and S. R. Daniels Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing Circulation, April 10, 2007; 115(14): 1948 - 1967. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |